EXPLORING THE ROLE OF OZEMPIC IN WEIGHT MANAGEMENT FOR DIABETIC PATIENTS AND ITS CORRELATION WITH IMPROVED GLYCAEMIC CONTROL COMPARING TRADITIONAL INSULIN THERAPY
Main Article Content
Keywords
Ozempic, Semaglutide, Diabetes Management, Type 2 Diabetes, Glycaemic Control
Abstract
This study aimed to evaluate the effectiveness of Ozempic (semaglutide), a GLP-1 receptor agonist, in weight management and glycaemic control among diabetic patients in Pakistan, compared to traditional insulin therapy.
Methodology: A cross-sectional study was conducted from 2021 to 2024 across various private and government hospitals in Pakistan, involving 250 type 2 diabetic patients. The participants were divided into two groups: 125 patients received Ozempic, while 125 were treated with conventional insulin therapy. The primary outcomes measured included HbA1c levels, fasting plasma glucose, body weight, BMI, treatment satisfaction, and quality of life.
Results: The Ozempic group demonstrated a significant reduction in HbA1c (-1.4% vs. -0.7%, p<0.001), body weight (-4.8 kg vs. +1.5 kg, p<0.001), and BMI (-1.6 kg/m² vs. +0.5 kg/m², p<0.001) compared to the insulin group. Furthermore, patients treated with Ozempic reported higher treatment satisfaction and improved quality of life.
Conclusion: Ozempic presents a superior alternative to traditional insulin therapy for managing type 2 diabetes and associated obesity in Pakistan. It should be considered a first-line treatment to improve patient outcomes and reduce the burden of diabetes-related complications.
References
2. Haider, F., Imam, S., Tulp, O., & Rizvi, S. (2024). A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated Comorbidities.
3. Huang, X., Wu, M., Lin, J., Mou, L., Zhang, Y., & Jiang, J. (2024). Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis. Medicine, 103(21), e38236.
4. Lupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024). Pharmacologic management of obesity‐updates on approved medications, indications and risks. Alimentary Pharmacology & Therapeutics, 59(4), 475-491.
5. Alruwaily, A. (2024). The impact intentional weight loss can have on patients living with sleep apnea (Doctoral dissertation, University College Dublin. School of Medicine).
6. Sivo-Souza, K. (2024). Diabetic Management with GLP1-RA Ozempic and Diabetic Education.
7. Al-Horani, R. A., Aliter, K. F., & Aliter, H. F. (2024). Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity. Current Diabetes Reviews, 20(8), 84-97.
8. Laine, E. (2024). Novo Nordisk and framings of obesity for corporate goals.
9. Xie, Y., He, Q., Wang, X., & Wang, J. (2024). Opportunities and challenges of incretins-based hypoglycemic agents treating of T2DM from the insight of physiological disposition. Authorea Preprints.
10. Machado, M. F., Shunk, T., Hansen, G., Harvey, C., Fulford, B., Hauf, S., ... & De Gaetano, J. S. (2024). Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review. Cureus, 16(8).
11. Palana, C., Aburumman, A., Kachungunu, C. N. K., Hocquard, A., Avila, G., Pagana, A., ... & John, T. (2024). Analyzing The Effects Of Semaglutide (Ozempic/Wegovy) On Metabolism: Investigating Correlations With Weight Reduction. Journal of Positive Psychology and Wellbeing, 8(4), 19-41.
12. Seddio, A. E., Gouzoulis, M., Vasudevan, R., Dhodapkar, M., Jabbouri, S., Zhu, J., ... & Grauer, J. N. (2024). 100. Semaglutide associated with improved postoperative outcomes following single-level posterior lumbar fusion for patients with type II diabetes. The Spine Journal, 24(9), S52-S53.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Muqadas Mukhtar
RNBN with Intrinsic Analytic Inc, Winnipeg Canada.
Shah Umam
Assistant Professor, Department of Medicine, MTI Khyber Teaching Hospital, Pakistan
Iqra Mukhtar
House Officer, Al-Nafees Medical College and Hospital, Islamabad, Pakistan.
Muhammad Usman Amiruddin
Consultant Plastic Surgeon, UA Aesthetics, Lahore, Pakistan.
Tehseen Tanveer
Medical Specialist, KRL Hospital, Islamabad, Pakistan.
Jawaria Bibi
Senior Registrar, OMFS Department, Aesthetic Physician, HBS Medical and Dental College and Hospital, Islamabad, Pakistan.